NCT03815279 - A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2028

Conditions

Multiple MyelomaSmoldering Multiple Myeloma

Interventions

DRUG

Carfilzomib

Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24

DRUG

Lenalidomide

Lenalidomide PO once daily on days 1-21 of a 28 day cycle

DRUG

Dexamethasone

Dexamethasone will be administered weekly

Trial Locations (1)

Landspitali University Hospital, Reykjavik